Recombinant GPC3 (Codrituzumab Biosimilar) 抗体
Quick Overview for Recombinant GPC3 (Codrituzumab Biosimilar) 抗体 (ABIN7581429)
抗原
抗体类型
适用
宿主
克隆类型
标记
应用范围
-
-
Expression System
- CHO Cells
-
原理
- Anti-GPC3 / Glypican-3 Reference Antibody (codrituzumab)
-
序列
- QVQLVQSGAE VKKPGASVKV SCKASGYTFT DYEMHWVRQA PGQGLEWMGA LDPKTGDTAY SQKFKGRVTL TADKSTSTAY MELSSLTSED TAVYYCTRFY SYTYWGQGTL VTVSSASTKG PSVFPLAPSS KSTSGGTAAL GCLVKDYFPE PVTVSWNSGA LTSGVHTFPA VLQSSGLYSL SSVVTVPSSS LGTQTYICNV NHKPSNTKVD KKVEPKSCDK THTCPPCPAP ELLGGPSVFL FPPKPKDTLM ISRTPEVTCV VVDVSHEDPE VKFNWYVDGV EVHNAKTKPR EEQYNSTYRV VSVLTVLHQD WLNGKEYKCK VSNKALPAPI EKTISKAKGQ PREPQVYTLP PSRDELTKNQ VSLTCLVKGF YPSDIAVEWE SNGQPENNYK TTPPVLDSDG SFFLYSKLTV DKSRWQQGNV FSCSVMHEAL HNHYTQKSLS LSPGK,DVVMTQSPLS LPVTPGEPAS ISCRSSQSLV HSNRNTYLHW YLQKPGQSPQ LLIYKVSNRF SGVPDRFSGS GSGTDFTLKI SRVEAEDVGV YYCSQNTHVP PTFGQGTKLE IKRTVAAPSV FIFPPSDEQL KSGTASVVCL LNNFYPREAK VQWKVDNALQ SGNSQESVTE QDSKDSTYSL SSTLTLSKAD YEKHKVYACE VTHQGLSSPV TKSFNRGEC
-
产品特性
- Anti-GPC3 / Glypican-3 Reference Antibody (codrituzumab) is expressed from CHO. The heavy chain type is huIgG1, and the light chain type is hukappa. It has a predicted MW of 145.5 kDa.
-
纯度
- >95 %
-
亚型
- IgG1
-
-
-
-
应用备注
- Optimal working dilution should be determined by the investigator.
-
说明
-
Therapeutic Agents by Target and Mechanism: GPC3 inhibitors, ADCC, Antibody-dependent phagocytosis
Conditions: Liver Cancer
-
限制
- 仅限研究用
-
-
-
状态
- Lyophilized
-
浓度
- 1 mg/mL
-
缓冲液
- 25 mM histidine, 8 % sucrose, 0.01 % Tween80 pH 6.2
-
储存条件
- 4 °C,-80 °C
-
储存方法
- +4°C,-80°C
-
-
- GPC3 (Codrituzumab Biosimilar)
-
物质类
- Biosimilar
-
背景
- Synonyms: GPC3
-
分子量
- 145.5 kDa
-
UniProt
- P51654
抗原
-